

Date: 18 October 2019

**Dechra® Pharmaceuticals PLC**

**Results of Annual General Meeting (AGM)**

AGM Meeting Date: 1.00 pm on 18 October 2019

Issued Share Capital at meeting date: 102,810,767

Number of shareholders in attendance: 9

All resolutions were passed on a show of hands.

Details of the proxy voting instructions lodged prior to the AGM are set out below:

|  |  |  |  |
| --- | --- | --- | --- |
| **Resolution (No. as noted on proxy form)** | **Total For (1)** | **Total Against** | **Withheld (2)** |
|  | **No. of votes** | **% of vote** | **No. of votes** | **% of vote** | **No. of votes** |
| Resolution 1:To receive the accounts, the Strategic Report, the Directors’ Report and the Auditor’s Report | 73,600,333 | 100 | 1,169 | 0.00 | 124,694 |
| Resolution 2:To approve the Directors’ Remuneration Report | 72,519,866 | 99.27 | 533,633 | 0.73 | 672,695 |
| Resolution 3:To declare a final dividend | 73,723,024 | 100 | 3,172 | 0.00 | 0 |
| Resolution 4:To elect Lisa Bright | 71,027,627 | 96.34 | 2,697,283 | 3.66 | 1,286 |
| Resolution 5:To re-elect William Anthony Rice | 64,700,457 | 88.18 | 8,674,437 | 11.82 | 351,301 |
| Resolution 6:To re-elect Ian Page | 72,894,442 | 98.87 | 830,875 | 1.13 | 879 |
| Resolution 7:To re-elect Anthony Griffin | 72,692,473 | 98.87 | 829,706 | 1.13 | 204,017 |
| Resolution 8:To re-elect Julian Heslop | 72,655,439 | 98.55 | 1,069,878 | 1.45 | 879 |
| Resolution 9:To re-elect Ishbel Macpherson | 72,432,244 | 98.32 | 1,238,292 | 1.68 | 55,660 |
| Resolution 10:To re-elect Lawson Macartney | 72,658,987 | 98.55 | 1,066,330 | 1.45 | 879 |
| Resolution 11:To re-appoint PricewaterhouseCoopers as external auditor of the Company | 73,101,156 | 99.98 | 11,756 | 0.02 | 613,283 |
| Resolution 12:To authorise the Audit Committee to determine the remuneration of the external auditor | 73,723,991 | 100 | 2,205 | 0.00 | 0 |
| Resolution 13:To authorise the Directors to allot shares to specific limits | 69,401,484 | 94.13 | 4,324,496 | 5.87 | 216 |
| Resolution 14:To disapply the pre-emption rights | 73,525,799 | 99.73 | 199,168 | 0.27 | 1,229 |
| Resolution 15:To disapply additional pre-emption rights | 71,956,054 | 97.60 | 1,768,826 | 2.40 | 1,315 |
| Resolution 16:To authorise the Company to purchase its own shares | 72,768,511 | 99.00 | 734,677 | 1.00 | 223,007 |
| Resolution 17:To call general meetings (other than an AGM) on not less than 14 clear days’ notice | 72,473,824 | 98.30 | 1,252,372 | 1.70 | 0 |
| Resolution 18:To adopt New Articles of Association | 73,625,816 | 99.87 | 99,231 | 0.13 | 1,149 |

Notes

1. Includes discretionary votes.
2. A “vote withheld” is not a vote in law and is not counted in the calculation of the proportion of votes “For” and “Against” a resolution.
3. Resolutions 1 to 13 were ordinary resolutions, requiring more than 50% of shareholder votes to be “For” the resolutions.
4. Resolutions 14 to 18 were special resolutions, requiring more than 75% of shareholder votes to be “For” the resolutions.
5. Votes tendered in respect of 73,726,196 shares representing 71.71% of the issued share capital.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further information, please contact:

Melanie Hall, Company Secretary

Telephone number: 01606 814730

**About Dechra**

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra’s products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: [www.dechra.com](http://www.dechra.com).

**Trademarks**

Trademarks appear throughout this document in italics. Dechra and the Dechra “D” logo are registered trademarks of Dechra Pharmaceuticals PLC.